Johan Stranne, MD, PhD, Sahlgrenska University Hospital, Gothenburg, Sweden, discusses the role of active surveillance versus intervention in patients with intermediate-risk prostate cancer, highlighting the importance of taking into consideration risk of development as well as the patients' perspective. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
